Record-Breaking Price Movement
On 09 Jun 2026, Venus Remedies Ltd touched an intraday high of Rs. 1,729.95, marking a new 52-week and all-time peak for the stock. Despite closing the day with a decline of 4.80% at Rs. 1,613.40, the stock demonstrated notable volatility with an intraday price range spanning from Rs. 1,603 to Rs. 1,729.95, reflecting a 35.15% weighted average volatility. The stock’s performance on this day underperformed the Pharmaceuticals & Biotechnology sector by 4.04% and the broader Sensex benchmark by 5.33%.
Strong Upward Trend and Moving Averages
Venus Remedies Ltd is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a sustained bullish momentum. The overall technical trend remains positive, having shifted from a mildly bullish stance to a more pronounced bullish trend since 12 Mar 2026, when the stock was priced at Rs. 927.50.
Exceptional Long-Term Performance
The stock’s long-term returns have been remarkable. Over the past decade, Venus Remedies Ltd has delivered a staggering 1,808.02% return, vastly outperforming the Sensex’s 176.18% gain during the same period. The company’s 5-year return stands at 408.34%, compared to the Sensex’s 42.30%, while the 3-year return is an impressive 605.76% against the Sensex’s 18.03%. Even in the shorter term, the stock has outpaced the market significantly, with a 1-year return of 261.62% versus the Sensex’s negative 10.35% and a year-to-date return of 109.34% compared to the Sensex’s -13.27%.
Financial Strength and Growth Metrics
Venus Remedies Ltd’s financials reveal a company in robust health. The firm is net-debt free, reflecting a strong balance sheet and prudent capital management. Operating profit has grown at an annualised rate of 45.72%, while net profit surged by 126.19% in the most recent quarter ending March 2026. The company has reported positive results for six consecutive quarters, with Profit Before Tax (excluding other income) reaching Rs. 56.66 crores, a growth of 133.36% year-on-year.
Net sales for the quarter stood at Rs. 259.40 crores, up 33.05%, while the company’s Return on Capital Employed (ROCE) hit a high of 19.85%. Return on Equity (ROE) is recorded at 15.5%, with a Price to Book Value ratio of 3.4, indicating a fair valuation relative to its growth and profitability metrics. The Price to Earnings (P/E) ratio stands at 22x, supported by a low PEG ratio of 0.13x, signalling that earnings growth is outpacing the stock price increase.
Institutional Participation and Market Capitalisation
Institutional investors have increased their stake by 0.72% over the previous quarter, now collectively holding 4% of the company’s shares. This growing institutional interest reflects confidence in the company’s fundamentals and growth prospects. Venus Remedies Ltd is classified as a micro-cap company, which has nonetheless demonstrated significant market capitalisation growth aligned with its stock price appreciation.
Quality and Risk Assessment
The company holds an average quality grade based on long-term financial performance. Key strengths include excellent capital structure with low debt levels, strong interest coverage at 50.94 times EBIT to interest, and zero promoter share pledging. The company’s average net debt to equity ratio is negative, confirming its net cash position. While the average Return on Capital Employed and Return on Equity over five years are modest at 9.53% and 8.61% respectively, recent quarterly figures indicate marked improvement in profitability and capital efficiency.
Recent Quarterly Highlights
The March 2026 quarter was particularly strong, with the highest recorded Profit Before Depreciation, Interest, and Tax (PBDIT) at Rs. 63.42 crores and an operating profit margin of 24.45%. Earnings per share (EPS) for the quarter reached Rs. 35.53, the highest in recent periods. Despite a dip in cash and cash equivalents to Rs. 29.61 crores, the overall financial trend remains positive.
Valuation Multiples and Dividend Information
Venus Remedies Ltd’s valuation multiples reflect its growth profile. The EV/EBITDA ratio is 14.69x, and EV/EBIT stands at 17.79x, consistent with a company in a growth phase. The stock’s EV/Sales multiple is 2.81x, and EV/Capital Employed is 3.78x. The company declared a dividend of Rs. 3 per share, with the last ex-dividend date recorded on 23 Sep 2013. Dividend yield and payout ratios are not currently available.
Volatility and Trading Activity
Trading volumes have shown a significant increase, with a 1-month delivery volume change of 70.43% and a 1-day delivery change of 42.85% compared to the 5-day average. On 08 Jun 2026, the stock recorded a delivery volume of 1.93 lakh shares, representing 47.15% of total volume, indicating active participation by market participants.
Summary of Market Performance
Venus Remedies Ltd’s stock has demonstrated exceptional resilience and growth, outperforming the broader market and its sector peers consistently over multiple time horizons. The achievement of an all-time high price of Rs. 1,729.95 is a testament to the company’s strong fundamentals, sustained profitability, and effective capital management. While the stock experienced a short-term pullback following 11 consecutive days of gains, its overall trend remains bullish, supported by solid technical indicators and improving financial metrics.
